Previous close | 329.00 |
Open | 335.00 |
Bid | 334.70 x 0 |
Ask | 338.70 x 0 |
Day's range | 335.00 - 335.00 |
52-week range | 220.40 - 335.00 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Today, global health company The Cigna Group (NYSE:CI), will outline its growth and innovation strategies at its 2024 Investor Day. In addition, the company is raising its long-term average annual adjusted EPS1 growth target to 10%-14% and is reaffirming its 2024 adjusted EPS1 guidance of at least $28.25.
Global health company The Cigna Group (NYSE:CI) announced today that Brian Evanko, executive vice president and chief financial officer, will present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024, in Miami, FL.
The Cigna Group (NYSE: CI) announced today the pricing terms of its previously announced offers to purchase for cash (1) any and all of The Cigna Group's (the "Company") 3.50% Senior Notes due 2024 and Evernorth Health, Inc.'s ("Evernorth") 3.50% Senior Notes due 2024 (collectively, the "Any and All Notes," and such tender offer, the "Any and All Tender Offer") and (2) up to $1,550,000,000 aggregate principal amount (the "Maximum Tender Offer Amount") of the Company's 4.125% Senior Notes due 202